1. Short title This Act may be cited as the Opioid Abuse Deterrence, Research, and Recovery Act of 2017 . 2. Registration requirements for prescribers Section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ) is amended by adding at the end the following: (k) (1) The Attorney General shall not register, or renew the registration of, a practitioner under subsection (f) who is licensed under State law to prescribe controlled substances in schedule II or III, unless the practitioner submits to the Attorney General, for each such registration or renewal request, a certification that the practitioner, during the applicable registration period, except as provided in paragraph (2), will not prescribe any schedule II or III opioid for the initial treatment of acute pain in an amount in excess of the lesser of— (A) a 7-day supply (for which no refill is available); or (B) an opioid prescription limit established under the law of the State where the prescribing occurs. (2) The certification required by paragraph (1) shall not prohibit a practitioner from— (A) prescribing, for the treatment of an opioid use disorder, a schedule II or III opioid that is approved by the Food and Drug Administration for such treatment; (B) prescribing, for immediate, post-operative pain relief, a schedule II or III opioid; or (C) prescribing a schedule II or III opioid in an amount in excess of a 7-day supply if the practitioner— (i) provides a specific reason for exceeding the 7-day limit that is in accordance with a clear medical standard of care whose implementation necessarily exceeds such limit; (ii) documents such reason and medical standard of care in the patient’s medical record; and (iii) consults the applicable State’s electronic health record system or prescription drug monitoring program. (3) In this subsection, the term acute pain — (A) means pain with abrupt onset and caused by an injury or other process that is diagnostically determined to have minimal risk of escalating in intensity